CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hainan Huluwa Pharmaceutical Grop Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hainan Huluwa Pharmaceutical Grop Co Ltd
No. 30, Andu 1st Road, Xiuying District
Phone: +86 89868634767p:+86 89868634767 HAIKOU, HAN  570311  China Ticker: 605199605199
Business Summary
Hainan Huluwa Pharmaceutical Group Co Ltd is a China-based company principally involved in the research and development, manufacturing and sales of Chinese patent medicines and chemical drugs. Its products are used in the pharmaceutical fields of respiratory system, digestive system, systemic anti-infection, including pediatric lung heat cough asthma granules, bromhexine hydrochloride for injection, compound Banlangen granules, Keke tablets, omeprazole enteric-coated capsules , Changyanning (capsules and granules), omeprazole sodium for injection, sodium diisopropylamine dichloroacetate for injection and cefixime dispersible tablets, among others. The Company also provides gynecological medicine, cardiovascular system medicine and neurological system medicine preparation products. The Company operates its businesses in the domestic market.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager JingpingLiu 52 2/26/2016 2/26/2016
Chief Financial Officer, Deputy General Manager, Director HuiYu 39 4/17/2023 7/8/2022
Deputy General Manager, Director JunlingLi 54 8/19/2019 8/19/2019
9 additional Officers and Directors records available in full report.

General Information
Number of Employees: 2,468 (As of 12/31/2023)
Outstanding Shares: 400,108,752 (As of 9/30/2024)
Shareholders: 33,933
Stock Exchange: SHA
Fax Number: +86 89868631245


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024